Please click on the ID to see detailed information about each entry.
The total number entries retrieved from this search are| ID | Sequence | Name | Nature of peptide or cargo | Assay | Tissue permeability | Tissue Sample | PUBMED ID |
|---|---|---|---|---|---|---|---|
| 1117 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 64.9±8.8% degraded | Interior skin surface of dermatomed skin (DS) of porcine | 19486932 |
| 1118 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 15±4.1% degraded | Interior skin surface of heat separated epidermis (HSE) of porcine | 19486932 |
| 1119 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 100% degraded | Interior skin surface of full thickness skin (FTS) of porcine | 19486932 |
| 1120 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 87.8±4.4% degraded | Interior skin surface of dermatomed skin (DS) of porcine | 19486932 |
| 1121 | pGlu-HWSYwLRPG | Triptorelin | Luteinizing hormone releasing hormone (LHRH) superagonist | Franz diffusion cell, HPLC | 51.3±6% degraded | Interior skin surface of heat separated epidermis (HSE) of porcine | 19486932 |
| 1199 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 2.37 ± 0.94 µg h−1 cm−2 at 100% DC | Human cadaver skin | 14757511 |
| 1200 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 9.87 ± 4.91 µg h−1 cm−2 at 75% pulsed DC | Human cadaver skin | 14757511 |
| 1201 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 5.57 ± 2.27 µg h−1 cm−2 at 50% pulsed DC | Human cadaver skin | 14757511 |
| 1202 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 1.21 ± 0.76 µg h−1 cm−2 at 75%+/25%− AC | Human cadaver skin | 14757511 |
| 1203 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 0.006 ± 0.004 µg h−1 cm−2 at 50%+/50%− AC | Human cadaver skin | 14757511 |
| 1204 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 1.99 ± 2.04 µg h−1 cm−2 at 100% DC | Human cadaver skin | 14757511 |
| 1205 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 6.47 ± 0.87 µg h−1 cm−2 at 75% DC | Human cadaver skin | 14757511 |
| 1206 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 0.96 ± 0.79 µg h−1 cm−2 at 50% pulsed DC | Human cadaver skin | 14757511 |
| 1207 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 3.33 ± 1.04 µg h−1 cm−2 at 75%+/25%- AC | Human cadaver skin | 14757511 |
| 1208 | pGlu-HWSY-D-2-Nal-LRPG | Nafarelin | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | Nafarelin flux= 0.15 ± 0.09 µg h−1 cm−2 at 50%+/50%- AC | Human cadaver skin | 14757511 |
| 1209 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 12.39 ± 5.32 µg h−1 cm−2 at 75% pulsed DC (500 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1210 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 5.97 ± 3.20 µg h−1 cm−2 at 50% pulsed DC (500 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1211 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux=9.07 ± 4.28 µg h−1 cm−2 at 25% pulsed DC (500 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1212 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 8.70±3.56 µg h−1 cm−2 at 75% pulsed DC (5 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1213 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 7.31±1.94 µg h−1 cm−2 at 50% pulsed DC (5 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1214 | pGlu-HWSYGLRPG | LHRH | Peptides containing closely juxtapositioned cationic and lipohilic residues are able to inhibit their own transport across the skin even under the influence of iontophoretic current. | HPLC | LHRH flux= 9.35±1.98 µg h−1 cm−2 at 25% pulsed DC (5 Hz) | Epidermis of human cadaver skin | 14757511 |
| 1229 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-11.1 ± 0.7, Basal skin blood flow(PU)-378 ± 47, Heart rate(min-1)-424 ± 26, Respiratory rate(min-1)-113 ± 8, pH-7.38 ± 0.02, pCO2(kPa)-7.07 ± 0.37 and pO2(kPa)-7.91 ± 0.25 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1230 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.8 ± 1.0, Basal skin blood flow(PU)-421 ± 4, Heart rate(min-1)-417 ± 23, Respiratory rate(min-1)-118 ± 6, pH-7.39 ± 0.01, pCO2(kPa)-6.82 ± 0.27 and pO2(kPa)-8.43 ± 0.24 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1231 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.5 ± 1.0, Basal skin blood flow(PU)-454 ± 23, Heart rate(min-1)-423 ± 23, Respiratory rate(min-1)-123 ± 6, pH-7.40 ± 0.02, pCO2(pKa)-6.46 ± 0.31 and pO2(pKa)-9.87 ± 1.49 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1232 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-9.5 ± 0.8, Basal skin blood flow(PU)-348 ± 62, Heart rate(min-1)-419 ± 26, Respiratory rate(min-1)-115 ± 7, pH-7.37 ± 0.02, pCO2(pKa)-7.05 ± 0.56 and pO2(pKa)-7.39 ± 0.33 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1233 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-11.3 ± 0.7, Basal skin blood flow(PU)-370 ± 55, Heart rate(min-1)-329 ± 12, Respiratory rate(min-1)-89 ± 5, pH-7.33 ± 0.01, pCO2(pKa)-8.31 ± 0.25 and pO2(pKa)-9.24 ± 1.03 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1234 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-9.9 ± 0.8, Basal skin blood flow(PU)-358 ± 47, Heart rate(min-1)-349 ± 15, Respiratory rate(min-1)-101 ± 5, pH-7.33 ± 0.01, pCO2(pKa)-7.85 ± 0.23 and pO2(pKa)-9.30 ± 0.71 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1235 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-9.0 ± 0.5, Basal skin blood flow(PU)-287 ± 51, Heart rate(min-1)-353 ± 14, Respiratory rate(min-1)-98 ± 4, pH-7.33 ± 0.01, pCO2(pKa)-7.72 ± 0.34 and pO2(pKa)-8.43 ± 0.63 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1236 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-8.2 ± 0.4, Basal skin blood flow(PU)-244 ± 50, Heart rate(min-1)-359 ± 11, Respiratory rate(min-1)-91 ± 9, pH-7.35 ± 0.02, pCO2(pKa)-6.89 ± 0.33 and pO2(pKa)-10.8 ± 1.55 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1237 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-11.2 ± 0.2, Basal skin blood flow(PU)-380 ± 44, Heart rate(min-1)-387 ± 18, Respiratory rate(min-1)-105 ± 10, pH-7.36 ± 0.03, pCO2(pKa)-7.42 ± 0.49 and pO2(pKa)-8.32 ± 0.70 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1238 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.5 ± 0.5, Basal skin blood flow(PU)-305 ± 72, Heart rate(min-1)-385 ± 3, Respiratory rate(min-1)-113 ± 5, pH-7.39 ± 0.01, pCO2(pKa)-6.72 ± 0.08 and pO2(pKa)-7.99 ± 0.60 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1239 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.1 ± 0.5, Basal skin blood flow(PU)-259 ± 69, Heart rate(min-1)-378 ± 4, Respiratory rate(min-1)-110 ± 8, pH-7.41 ± 0.01, pCO2(pKa)-6.51 ± 0.04 and pO2(pKa)-8.44 ± 0.46 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1240 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-9.9 ± 0.8, Basal skin blood flow(PU)-202 ± 71, Heart rate(min-1)-372 ± 17, Respiratory rate(min-1)-101 ± 4, pH-7.40 ± 0.01, pCO2(pKa)-6.58 ± 0.20 and pO2(pKa)-8.73 ± 0.60 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1241 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-11.0 ± 0.31, Basal skin blood flow(PU)-382 ± 32, Heart rate(min-1)-400 ± 8, Respiratory rate(min-1)-116 ± 7, pH-7.35 ± 0.01, pCO2(pKa)-7.73 ± 0.24 and pO2(pKa)-9.59 ± 1.04 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1242 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.7 ± 0.31, Basal skin blood flow(PU)-294 ± 42, Heart rate(min-1)-404 ± 10, Respiratory rate(min-1)-116 ± 7, pH-7.36 ± 0.01, pCO2(pKa)-7.14 ± 0.22 and pO2(pKa)-8.57 ± 0.31 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1243 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.3 ± 0.33, Basal skin blood flow(PU)-213 ± 48, Heart rate(min-1)-407 ± 13, Respiratory rate(min-1)-107 ± 9, pH-7.38 ± 0.01, pCO2(pKa)-6.62 ± 0.24 and pO2(pKa)-10.6 ± 1.13 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1244 | pGlu-3-methyl-HP | M-TRH | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-9.8 ± 0.52, Basal skin blood flow(PU)-212 ± 54, Heart rate(min-1)-412 ± 8, Respiratory rate(min-1)-102 ± 13, pH-7.38 ± 0.01, pCO2(pKa)-6.52 ± 0.22 and pO2(pKa)-9.33 ± 0.58 | Stratum corneum of the abdominal area of male Sprague-Dawley rats | 11179600 |
| 1245 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND) | Radioimmunoassay and Liquid Scintillation Technique | Permeability coefficient (Kp)= 18.4*105 cm/h, Cumulative amount= 24.9± 1.7 µg/cm2, Enhancement factor (EF) =3.4 | Human epidermal membrane | 10205635 |
| 1246 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND) | Radioimmunoassay and Liquid Scintillation Technique | Permeability coefficient (Kp)= 16.6*105 cm/h, Cumulative amount= 18.5± 2.1 µg/cm2, Enhancement factor (EF) =3.1 | Human epidermal membrane | 10205635 |
| 1247 | pGlu-HP | Thyrotropin-releasing hormone (TRH) | It is a tripeptide that used in the treatment of brain and spinal cord injury and certain CNS disorders, including Alzheimer’s disease and motor neuron disease (MND) | Radioimmunoassay and Liquid Scintillation Technique | Permeability coefficient (Kp)= 5.4*105 cm/h, Cumulative amount= 7.8± 1.7 µg/cm2, Enhancement factor (EF) =0 | Human epidermal membrane | 10205635 |
| 1248 | pGlu-3-methyl-HP | M-TRH | Analogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide. | Liquid Scintillation Technique | Permeability coefficient (Kp)= 32.0*105 cm/h, Cumulative amount= 41.5±4.9 µg/cm2, Enhancement factor (EF) =4.7 | Human epidermal membrane | 10205635 |
| 1249 | pGlu-3-methyl-HP | M-TRH | Analogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide. | Liquid Scintillation Technique | Permeability coefficient (Kp)=20.2*105 cm/h, Cumulative amount= 20.4± 3.6µg/cm2, Enhancement factor (EF) =3.0 | Human epidermal membrane | 10205635 |
| 1250 | pGlu-3-methyl-HP | M-TRH | Analogue of TRH i.e. M-TRH is a potent analogue and stimulates the release of TSH from the pituitary seven to eight times that of the parental tripeptide. | Liquid Scintillation Technique | Permeability coefficient (Kp)= 6.8*105 cm/h, Cumulative amount= 8.6± 1.0 µg/cm2, Enhancement factor (EF) =0 | Human epidermal membrane | 10205635 |
| 1345 | pGlu-EDSG | Epidermal pentapeptide | It induces a moderate but long-lasting inhibition of epidermal cell proliferation when given at low (picomol) doses but stimulates epidermal cell proliferation at higher doses | Colcemid-arrested mitoses and labelled cells were counted per 12 mm of interfollicular epidermis in 5 pm paraffin sections stationed with haematoxylin in the former and dipcoated with NTB 2 emulsion and incubated for 3 weeks at 0-4 ͦC for later. The statistical evaluations were made according to the Wilcoxon's rank sum test. | Significant mitotic rate inhibition initially and on day 7 after an overshoot on day 6 | Back skin of female hairless mice (hr/hr) | 1977237 |
| 1346 | pGlu-EDSG | Epidermal pentapeptide | It induces a moderate but long-lasting inhibition of epidermal cell proliferation when given at low (picomol) doses but stimulates epidermal cell proliferation at higher doses | Colcemid-arrested mitoses and labelled cells were counted per 12 mm of interfollicular epidermis in 5 pm paraffin sections stationed with haematoxylin in the former and dipcoated with NTB 2 emulsion and incubated for 3 weeks at 0-4 ͦC for later. The statistical evaluations were made according to the Wilcoxon's rank sum test. | Initial increase in mitotic rate, peaking on day 2, from day 2 to day 10, mitotic rate was lower than normal. | Back skin of female hairless mice (hr/hr) | 1977237 |
| 1347 | pGlu-EDSG | Epidermal pentapeptide | It induces a moderate but long-lasting inhibition of epidermal cell proliferation when given at low (picomol) doses but stimulates epidermal cell proliferation at higher doses | Colcemid-arrested mitoses and labelled cells were counted per 12 mm of interfollicular epidermis in 5 pm paraffin sections stationed with haematoxylin in the former and dipcoated with NTB 2 emulsion and incubated for 3 weeks at 0-4 ͦC for later. The statistical evaluations were made according to the Wilcoxon's rank sum test. | The mitotic rate was strongly increased with peaks at days 1, 3 and 6 (twice the control value). | Back skin of female hairless mice (hr/hr) | 1977237 |
| 1401 | Pyr-QRLGNQWAVGHLM | Bombesin | It may act as secretagogue in human nasal mucosa in vivo | Anterior rhinomanimetry, Nasal provocation, Lowrys method | Bombesin stimulates nasal secretion from submucosal glands and possibly epithelial cell without affecting vascular permeability. Total protein secretion was increased after 100 nmol (P=0.041) and 1000 nmol (P=0.009) of bombesin compared with baseline, significant lysozyme (24±3 µg/ml, P<0.05) secretion occurred after 1000 nmol. | Nasal mucosa of humans | 1733281 |